Whittier Trust’s Myriad Genetics MYGN Stock Holding History

Whittier Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-63	Closed	-$1K	–	1723
2022 Q2	$1K	Buy	+63	New	+$1.31K	﹤0.01%	1629

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Whittier Trust's MYGN Position: Q3 2022 in Review

Whittier Trust sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 63 shares — an estimated $1K sold.

Whittier Trust first reported a position in MYGN in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

Whittier Trust reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
Whittier Trust sold 63 Myriad Genetics shares in Q3 2022, an estimated $1K.
Whittier Trust first reported a position in Myriad Genetics in Q2 2022 and held it in 1 quarter.
Whittier Trust's Myriad Genetics position peaked at $1K in Q2 2022.
191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Whittier Trust's 13F filing for Q3 2022, filed 21 Oct 2022.